14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
REVS vs RECS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Columbia Research Enhanced Value ETF (REVS) is the stronger overall head-to-head candidate over Columbia Research Enhanced Core ETF (RECS) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). REVS carries a Unified Composite Score of 50.9/100 (HOLD) at $34.48 (N/M Forward P/E, N/A operating margin), whereas RECS carries 55.0/100 (HOLD) at $43.76 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While RECS currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. REVS 50.9/100 HOLD), REVS captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: REVS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.2); meanwhile RECS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REVS vs RECS. Trailing 12-month operating profitability (REVS N/A vs RECS N/A) and valuation multiples (REVS N/M vs RECS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ REVS vs RECS Key Questions & Quantitative Answers
As of Nov 16, 2026, Columbia Research Enhanced Value ETF (REVS) is the stronger overall head-to-head candidate over Columbia Research Enhanced Core ETF (RECS) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). REVS carries a Unified Composite Score of 50.9/100 (HOLD) at $34.48 (N/M Forward P/E, N/A operating margin), whereas RECS carries 55.0/100 (HOLD) at $43.76 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While RECS currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. REVS 50.9/100 HOLD), REVS captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: REVS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.2); meanwhile RECS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
REVS and RECS split Growth & Scale metrics: REVS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with RECS at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, REVS generates N/A in USD-normalized revenue versus N/A for RECS. In operating R&D and SG&A reinvestment, REVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RECS.
REVS and RECS trade at balanced relative valuation multiples. REVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RECS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REVS (N/A ROE) versus RECS (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, REVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 17% Vol realized risk). By comparison, RECS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.82β · 19% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.